What did Mayne Pharma Group (ASX:MYX) win in court against Cosette Pharmaceuticals?

The Supreme Court of New South Wales ordered Cosette Pharmaceuticals to pay Mayne Pharma Group (ASX:MYX) exactly $13,269,328.04 to cover legal costs.

What was the original legal dispute between Mayne Pharma (ASX:MYX) and Cosette?

The legal battle began in June 2025 when Mayne Pharma sued Cosette over the abrupt termination of a Scheme Implementation Deed signed in February 2025. In October 2025, the Court completely dismissed all of Cosette's claims and ruled in favour of Mayne Pharma.

Will Cosette Pharmaceuticals have to pay more than the $13.27 million awarded to Mayne Pharma?

Yes, the final financial impact for Cosette is expected to rise beyond the core $13.27 million fee. The Court is scheduled to hand down further orders shortly to finalise the exact amount of interest Cosette owes.

How does this court judgment impact Mayne Pharma's (ASX:MYX) balance sheet?

This judgment is a clear cash-flow positive for Mayne Pharma, recovering over $13.27 million in capital that had been tied up in legal expenses.

What does the court ruling mean for Mayne Pharma's (ASX:MYX) short-term share price?

With Mayne Pharma's share price trading at $2.36 at the time of reporting, this $13.27 million cash injection represents a solid, non-dilutive capital win. Traders often view the resolution of lingering litigation and the recovery of millions in cash as a de-risking event, which can provide positive near-term momentum for the stock.

How does this outcome change the medium-term investment thesis for Mayne Pharma (ASX:MYX)?

This ruling reinforces management's credibility, proving they successfully defended corporate agreements against wrongful termination. By recovering these substantial legal costs, Mayne Pharma avoids a hit to its earnings and retains capital that can be deployed toward core operations, R&D, or growth initiatives rather than being absorbed by legal friction.

Image for illustrative purposes only. Not a real photo.

Mayne Pharma wins $13.2M court costs order

Written by Liezl GambePublished May. 22 2026Last Updated May. 22 2026

Mayne Pharma Group (ASX:MYX) secured a legal victory after the Supreme Court of New South Wales ordered Cosette Pharmaceuticals to pay the company $13.3 million in legal costs, plus interest.

The ruling follows Mayne Pharma’s defence in a high-stakes corporate dispute that concluded last year.

The legal battle commenced in June 2025, when Mayne Pharma initiated proceedings against Cosette.

The dispute arose from Cosette’s purported termination of a scheme implementation deed, an agreement originally signed by both pharmaceutical companies in February 2025.

In October 2025, the Court delivered a definitive judgement in favour of Mayne Pharma, completely dismissing all of Cosette’s claims.

At the time, the Court also issued an adverse costs order against Cosette, establishing that the company would be responsible for covering Mayne Pharma’s legal expenses from the proceedings.

The judgement quantifies that obligation, locking in the multi-million-dollar figure. While the core legal costs have now been finalised, the financial impact for Cosette will likely rise.

The Court is expected to hand down further orders shortly to give full effect to the judgement.

The upcoming orders will finalise the exact amount of interest Cosette must pay, establish a strict timeframe for the payment, and address additional costs incurred by Mayne Pharma during its specific application for these legal fees.

At the time of reporting, Mayne Pharma’s share price was $2.36.